Sirona Biochem Corp., of Vancouver, British Columbia, and partner Jiangsu Wanbang Biopharmaceuticals Co. Ltd., of Xuzhou, China, said a $500,000 milestone payment to Wanbang was triggered by China's CNDA approval of a clinical trial application to start testing of SGLT2 inhibitor TFC-039 in type 2 diabetes.